Related Experiment Videos
A revised natural history model for primary sclerosing cholangitis
W R Kim1, T M Therneau, R H Wiesner
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn. 55905, USA.
Mayo Clinic Proceedings
|July 25, 2000
Summary
A new model estimates survival for primary sclerosing cholangitis (PSC) patients using routine clinical data, avoiding liver biopsies. This survival model offers accurate predictions based on simple tests.
Area of Science:
- Hepatology
- Clinical Medicine
- Biostatistics
Background:
- Primary sclerosing cholangitis (PSC) is a chronic liver disease.
- Accurate prognostication is crucial for managing PSC.
- Current models may require invasive procedures like liver biopsy.
Purpose of the Study:
- To develop and validate a novel natural history model for PSC.
- The model aims to predict patient survival using non-invasive clinical data.
- To eliminate the need for liver biopsy in PSC prognostication.
Main Methods:
- Cox proportional hazards analysis was used.
- A survival model was developed using data from 405 PSC patients.
- Independent validation was performed on a separate cohort of 124 PSC patients.
Main Results:
- A risk score formula was derived: R = 0.03 (age) + 0.54 loge (bilirubin) + 0.54 loge (AST) + 1.24 (variceal bleeding) - 0.84 (albumin).
- The model provided survival estimates up to 4 years.
- The model demonstrated good correlation between estimated and actual survival in the validation cohort.
Conclusions:
- A new, reproducible PSC survival model was created.
- The model utilizes readily available clinical variables: age, bilirubin, AST, albumin, and variceal bleeding history.
- This non-invasive model achieves accuracy comparable to existing methods.